Literature DB >> 12365576

Treatment of new pulmonary tuberculosis patients: what do allopathic doctors do in India?

R Prasad1, R G Nautiyal, P K Mukherji, A Jain, K Singh, R C Ahuja.   

Abstract

SETTING: Out- and in-patient services of the Department of Tuberculosis and Chest Diseases at King George's Medical College, Lucknow, India.
OBJECTIVE: To analyse the prescribing patterns of allopathic doctors for treatment of new cases of pulmonary tuberculosis (PTB), and to compare their practices with the current national and World Health Organization (WHO) recommendations.
DESIGN: A consecutive case series. Tuberculosis treatment practices of 449 primary doctors who had prescribed treatment for PTB to 218 patients were analysed.
RESULTS: Thirty-three different drug combination regimens were prescribed by 449 primary doctors. Approximately 45% (95%CI 41.5-49.9) of doctors did not practise the current NTP/WHO recommended drug regimens. Overall 75% (95%C1 70.4-78.8) of doctors made prescription errors with respect to one or more aspects of treatment, including treatment duration (64.5%) and drug dosages (30%). The most frequent prescription error was treatment for longer than necessary (60.2%; 95%CI 55.5-64.8). Overall, both chest specialists and non-chest specialists made prescription errors with almost equal frequency (77.5% vs. 72.2%, P = 0.228). The majority of the doctors (70.2%; 95%CI 65.7-74.5) used fixed-dose formulations of two to four drugs.
CONCLUSION: For effective tuberculosis control, strategies for targeted continuing medical education and auditing of the practices of all doctors need to be implemented without delay.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12365576

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  14 in total

1.  Alternative medicine: an ethnographic study of how practitioners of Indian medical systems manage TB in Mumbai.

Authors:  Andrew McDowell; Madhukar Pai
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-03       Impact factor: 2.184

Review 2.  Improving tuberculosis control through public-private collaboration in India: literature review.

Authors:  Puneet K Dewan; S S Lal; Knut Lonnroth; Fraser Wares; Mukund Uplekar; Suvanand Sahu; Reuben Granich; Lakhbir Singh Chauhan
Journal:  BMJ       Date:  2006-02-08

Review 3.  Multidrug-resistant to extensively drug resistant tuberculosis: what is next?

Authors:  Amita Jain; Pratima Dixit
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

4.  Factors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004.

Authors:  Nadia Valin; Gilles Hejblum; Isabelle Borget; Henri-Pierre Mallet; Fadi Antoun; Didier Che; Christos Chouaid
Journal:  BMC Public Health       Date:  2010-08-18       Impact factor: 3.295

Review 5.  Knowledge of tuberculosis-treatment prescription of health workers: a systematic review.

Authors:  Marieke J van der Werf; Miranda W Langendam; Emma Huitric; Davide Manissero
Journal:  Eur Respir J       Date:  2011-12-19       Impact factor: 16.671

6.  Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies.

Authors:  R Prasad
Journal:  Lung India       Date:  2012-04

7.  Public and/or private health care: tuberculosis patients' perspectives in Myanmar.

Authors:  Saw Saw; Lenore Manderson; Mridula Bandyopadhyay; Than Tun Sein; Myo Myo Mon; Win Maung
Journal:  Health Res Policy Syst       Date:  2009-07-28

8.  Medical management of genitourinary tuberculosis.

Authors:  Tamilarasu Kadhiravan; Surendra K Sharma
Journal:  Indian J Urol       Date:  2008-07

9.  What Can We Learn About the Processes of Regulation of Tuberculosis Medicines From the Experiences of Health Policy and System Actors in India, Tanzania, and Zambia?

Authors:  Kabir Sheikh; Mukund Uplekar
Journal:  Int J Health Policy Manag       Date:  2016-07-01

Review 10.  Nosocomial tuberculosis in India.

Authors:  Madhukar Pai; Shriprakash Kalantri; Ashutosh Nath Aggarwal; Dick Menzies; Henry M Blumberg
Journal:  Emerg Infect Dis       Date:  2006-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.